Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bionano Genomics, Inc. filings document the formal disclosures of a genome-analysis company commercializing optical genome mapping solutions, diagnostic testing services, genome-analysis software and nucleic acid extraction and purification technologies. Form 8-K reports record financial results, preliminary results, material agreements, securities offerings and executive leadership changes, while registration statements describe offered common stock, pre-funded warrants and warrant securities.
Proxy materials cover board elections, executive compensation, equity-award matters, shareholder voting and governance practices. The filing record also documents capital-structure changes, Nasdaq-listed common stock disclosures, risk factors and exhibits tied to Bionano’s OGM, VIA software, Ionic system and Bionano Laboratories operations.
Bionano Genomics, Inc. received an updated ownership report from Lind Global Fund III and related parties. The reporting group, which includes Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton, reports beneficial ownership of 1,050,000 shares of common stock, representing 9.35% of the outstanding class as of December 31, 2025.
The position consists of 525,000 Series E warrants and 525,000 Series F warrants to purchase common stock. These warrants are subject to a 9.9% beneficial ownership cap, meaning they cannot be exercised if such exercise would push the holders’ ownership above that threshold. The reporting persons certify that the securities were not acquired to change or influence control of Bionano Genomics.
CVI Investments, Inc. and Heights Capital Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 1,129,411 shares of Bionano Genomics, Inc. common stock, representing 9.9% of the class.
The reported position consists of shares issuable upon exercise of warrants, which are subject to 4.99% and 9.99% beneficial ownership limits that restrict further exercises above those thresholds. Bionano had 10,176,000 shares outstanding as of November 5, 2025. The reporting parties certify the holdings were not acquired to change or influence control of the company.
Bionano Genomics, Inc. reported an insider equity award to its Principal Accounting Officer, Mark Adamchak. On February 2, 2026, he received a stock option giving him the right to buy 10,890 shares of common stock at an exercise price of $1.27 per share. The option was granted at no cost and is held directly. According to the filing, 100% of the shares subject to the option vest on the one-year anniversary of the grant date, aligning his compensation more closely with the company’s future share performance.
Bionano Genomics reported an insider equity award for its Chief Medical Officer, Alka Chaubey. On 02/02/2026, Chaubey received a stock option to buy 27,737 shares of common stock at an exercise price of $1.27 per share. The option vests monthly over 48 months, beginning on the one-month anniversary of the vesting commencement date, and becomes fully vested and exercisable on the four-year anniversary of that commencement date. Following this grant, Chaubey beneficially owns 27,737 derivative securities directly, and the filing does not report any share sales.
Bionano Genomics chief operating officer Mark Oldakowski received a grant of 27,737 stock options on February 2, 2026. The options give him the right to buy Bionano Genomics common stock at an exercise price of $1.27 per share and expire on February 1, 2036.
The award vests in monthly installments over 48 months, starting one month after the vesting commencement date, so the option becomes fully vested and exercisable on the four-year anniversary of that commencement date. Following this grant, he beneficially owns 27,737 derivative securities directly.
Bionano Genomics, Inc. reported a new equity award for its General Counsel, Jonathan V. Dixon. On 02/02/2026, he received a stock option to buy 26,117 shares of common stock at an exercise price of $1.27 per share. The option vests monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, so it becomes fully vested and exercisable on the four-year anniversary of that date.
Bionano Genomics, Inc. reported that President and CEO, and director, Erik R. Holmlin received a grant of stock options on 02/02/2026. The award covers 69,484 options to buy common stock at an exercise price of $1.27 per share, expiring on 02/01/2036.
The options were awarded at a cost of $0 for the derivative itself and are held directly. They vest monthly over 48 months beginning one month after the vesting commencement date, so the option becomes fully vested and exercisable on the four-year anniversary of that date.
Bionano Genomics, Inc. filed a current report to disclose that it issued a press release with preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2025. The press release is provided as Exhibit 99.1, giving an early look at the company’s performance for that period. The report specifies that this preliminary financial information is being furnished, not filed, which limits its use for certain legal purposes. The document is signed on behalf of Bionano Genomics by President and Chief Executive Officer R. Erik Holmlin, Ph.D.
Bionano Genomics reported third‑quarter results showing higher revenue and a sharply narrower loss. Q3 2025 revenue was $7.367 million (vs. $6.073 million a year ago), driven by consumables and software, while net loss was $8.503 million (vs. $44.246 million). Cost of revenue fell significantly year over year, and operating expenses dropped without the prior year’s impairment and restructuring charges.
Liquidity remains tight. As of September 30, 2025, the company had $3.065 million in cash and cash equivalents, $18.516 million in investments, and $10.266 million in restricted short‑term investments. Management states there is “substantial doubt” about the company’s ability to continue as a going concern within 12 months without additional financing.
Convertible debentures outstanding totaled $10.266 million in principal, with monthly holder redemptions permitted and a conversion price of $16.20 per share subject to a beneficial ownership cap. Shares outstanding were 9,730,400 at quarter‑end and 10,176,000 as of November 5, 2025.
Bionano Genomics filed a Form 8-K stating it issued a press release reporting financial results for the third quarter ended September 30, 2025. The release is furnished under Item 2.02 and attached as Exhibit 99.1. In accordance with General Instruction B.2., the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically referenced.